MedTrace Logo

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

NCT03005873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-04-22

Study results available
· View outcomes & findings →

Summary

This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

TLC599 LD group

Single dose via intra-articular injection

DRUG

Normal Saline

Single dose via intra-articular injection

DRUG

TLC599 HD group

Single dose via intra-articular injection

Sponsors & Collaborators

  • Taiwan Liposome Company

    lead INDUSTRY

Principal Investigators

  • Yvonne Shih, PhD · Taiwan Liposome Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-16
Primary Completion
2018-07-04
Completion
2018-07-04

Countries

  • Australia
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03005873 on ClinicalTrials.gov